<DOC>
	<DOCNO>NCT00528073</DOCNO>
	<brief_summary>This study aim determine 3 dos non-absorbable antibiotic Rifaximin effective treat active moderate Crohn 's disease . Rifaximin tablet already market European country USA treat traveller 's diarrhoea . A new gastro-resistant form Rifaximin call Rifaximin-Extended Intestinal Release ( EIR ) use study . These tablet dissolve stomach , release gastro-resistant granule pass intestine deliver Rifaximin directly site disease . Rifaximin absorb , make effective greatly reduce frequency side effect .</brief_summary>
	<brief_title>Placebo Controlled Study 3 Doses Rifaximin-EIR Tablet Treat Moderate , Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>diagnosis Crohn 's disease localise ileum and/or colon , document either radiologically endoscopically least 3 month previously ; patient CDAI ≥ 220 ≤ 400 ; patient capable willing conform study protocol ; patient provide sign dated write informed consent . patient potentially need immediate surgery Crohn 's disease , include patient occlusive symptom and/or stenotic tract dilation ; patient active perianal Crohn 's disease ; patient infectious , ischemic , immunological disease gastrointestinal involvement ; patient symptoms attribute Short Bowel Syndrome previous surgery ; patient stoma ; patient affect upper gastrointestinal disease ( gastroduodenumjejunum Crohn 's disease ) alone combination colitis ileitis ; patient treat : oral steroid budesonide less 30 day prior screen ; i.v . steroid le 30 day prior screen ; antibiotic ( metronidazole , tinidazole , ciprofloxacin , clarithromycin ) less 15 day prior screen ; rectal steroid le 30 day prior screen visit ; antitumour necrosis factor ( antiTNF ) biological therapy less 6 month prior screen visit ; pregnant woman nurse mother ; female childbearing age ( unless surgically sterile ) without negative urine pregnancy test screen enrolment ; patient severe hepatic insufficiency ( Child C ) ; patient severe cardiac insufficiency ( NYHA New York Heart Association class 3 4 ) ; patient know hypersensitivity Rifaximin ; condition circumstance would prevent completion study interfere analysis study result , include history drug alcohol abuse , mental illness noncompliance treatment visit , immunological ( include HIV infection ) , haematological neoplastic disease ; withdrawal inform consent ; patient use investigational drug ( except biological therapy ) within 3 month prior screen ; patient donate 250 ml blood last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Rifaximin-EIR</keyword>
	<keyword>Crohn 's disease</keyword>
	<keyword>remission</keyword>
</DOC>